Literature DB >> 16481301

Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray.

Lei Xu1, You-Ming Li, Chao-Hui Yu, Lan Li, You-Shi Liu, Bao-Feng Zhang, Jing Fang, Qiong Zhou, Ying Hu, Hen-Jun Gao.   

Abstract

BACKGROUND: Pancreatic cancer development and progression is driven by the accumulation of genetic changes. In this study we constructed tissue microarray containing specimens from pancreatic cancer, adjacent non-cancer tissue and normal tissue to survey the expression of p53, p16 and cyclooxygenase-2 (COX-2).
METHODS: Tissue microarray containing 337 specimens from different stages of pancreatic cancer, adjacent non-cancer tissue and normal tissues was constructed, and the expression of p53, p16 and COX-2 was assayed by immunohistochemistry to consecutive formalin-fixed tissue microarray sections.
RESULTS: The expression of p53, p16 and COX-2 was significantly higher in tumorous tissues than in non-tumorous ones. A significant relationship was observed between p53 and COX-2, or p16 and COX-2. But no obvious correlation was seen between p53 and p16 expressions. Logistic regression analysis showed p53 and COX-2 as dependent predictors in pancreatic carcinogenesis, and a reciprocal relationship to neoplastic progression between p53 and COX-2.
CONCLUSION: Combination analysis of p53 and COX-2 may be useful in predicting pancreatic carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16481301

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  2 in total

1.  Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor.

Authors:  Chantale Charo; Vijaykumar Holla; Thiruvengadam Arumugam; Rosa Hwang; Peiying Yang; Raymond N Dubois; David G Menter; Craig D Logsdon; Vijaya Ramachandran
Journal:  Pancreas       Date:  2013-04       Impact factor: 3.327

2.  The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer cells.

Authors:  Yingqiang Zhong; Zhongsheng Xia; Juan Liu; Ying Lin; Hui Zan
Journal:  Oncol Rep       Date:  2011-12-19       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.